AKESOgen, Inc. Selected as a 2018 Atlanta Metro Export Challenge Winner
AKESOgen, Inc. Receives $5,000 Grant to Grow Internationally
ATLANTA – November 6th, 2018 AKESOgen, Inc. is a recipient of a $5,000 grant in the annual Atlanta Metro Export Challenge (Atlanta MEC), a grant program designed to engage small- and medium-sized businesses in metro Atlanta in the development of international sales plans.
Companies from all over the 29-county region, ranging in size from pre-revenue startups to small and established medium-sized businesses, applied to the program. Thirty companies were selected in the competition and will each receive a grant of $5,000 to apply towards the growth of their international business.
“AKESOgen is honored to be a winner of the Atlanta Metro Export Challenge. This grant will help AKESOgen expand its services internationally as a global forward thinking company.”
AKESOgen offers a wide array of genomic services that include next generation sequencing, microarray processing, DNA and RNA extractions for a variety of industries such as consumer genomics, biotech, pharma, academia, and forensics.
To see the full list of grant awardees, click here
The Atlanta MEC is one of many ways to engage small- and medium-sized companies in metro Atlanta in the development of their international business. Over the last two years, the program has given out more than $400,000 to metro Atlanta companies thanks to the generous sponsorship of JPMorgan Chase & Co, which again contributed $100,000 to this year’s program. Additional sponsorship came from the Metro Atlanta Chamber, UPS, Johnson Controls and Partnership Gwinnett.
“JPMorgan Chase is pleased to help metro Atlanta businesses grow in the international economy,” said David Balos, head of JPMorgan Chase’s Middle Market Banking group in Georgia. ‘’These grants will help companies spend time in their target markets to meet with distributors, partners, and potential customers. Seeing metro Atlanta companies grow their international business will consequently lead to job creation and growth of the metro Atlanta economy.”
The Atlanta MEC is being implemented by ORBATL, a regional partnership of metro Atlanta public and private leaders that enables businesses to grow in the global economy through trade and foreign direct investment.
AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.